Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-dose escalation study of LY2165766 with PET D2 receptor occupancy assessment
NL-OMON33530Phase 1Active, not recruiting
- Sponsor
- Chorus
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of LY2165766 in schizophrenia (3 arms), sponsored by Chorus. Primary endpoints: Safety, Pharmacology and 1 more. Started Oct 2008; status: active, not recruiting.
02
Drugs
LY2165766
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON33530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33530.